Background: Coronary endothelial dysfunction (CED) causes angina/ischemia in patients
with nonobstructive coronary artery disease (NOCAD). Patients with CED have decreased …

Background: Coronary microvascular dysfunction results in angina and adverse outcomes in
patients with evidence of ischemia and nonobstructive coronary artery disease; however, no …

Objectives: This study tested whether intramyocardial (IM) administration of mobilized,
purified autologous CD34+ cells would improve total exercise time (TET) and angina …

Background Previous studies have demonstrated that intramyocardial human CD34+ cells
may relieve symptoms and improve clinical outcomes in chronic refractory angina …

Preclinical trials indicate that CD34+ cells represent an effective angiogenic stem cell
component. Early-phase clinical trials suggest that intramyocardial administration of …

Rationale: A growing number of patients with coronary disease have refractory angina.
Preclinical and early-phase clinical data suggest that intramyocardial injection of autologous …

Background/Objectives: A large number of patients with coronary artery disease experience
angina that is not suitable for revascularization and is refractory to conventional medical …

Objectives: This study investigated the clinical and angiographic long-term outcomes of
intracoronary transfusion of circulation-derived CD34+ cells for patients with end-stage …

Ischemia with non-obstructive coronary arteries (INOCA) is an increasingly recognized
disease, with a prevalence of 3 to 4 million individuals, and is associated with a higher risk …

Objective: This study tested the hypothesis that intra-coronary transfusion of circulation-
derived autologous CD34+ cells can improve ischemia-related left ventricular dysfunction in …